R. M. Ortega1,2*, E. Rodríguez-Rodríguez2,3 and A. M. López-Sobaler1,2
1Departamento de Nutrición, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain
2Research group UCM-920030, Departamento de Nutrición, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain
3Sección Departamental de Química Analítica, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain

Abstract
This work provides a systematic review of all published randomised, controlled clinical trials (RCT) investigating the effects of n-3 PUFA intake on the prevention and treatment of non-neurodegenerative neuropsychiatric disorders. Five databases (PubMed, EMBASE, LILACS, CINAHL and The Cochrane Database) were searched for RCT in this area published up to April 2011. The selected studies all involved human participants and included a comparison group. Thirty eight studies were identified, which examined the influence of n-3 PUFA supplementation on the prevention/treatment of depression (non-perinatal) (n 23), perinatal depression (n 6) and attention deficit hyperactivity disorder (ADHD) (n 9). Great heterogeneity was noticed in terms of study design, the doses of n-3 PUFA administered, and study duration. Some benefit was noted with respect to the treatment of hyperactivity and depression in over half the examined studies, although the evidence was not conclusive. For any firm conclusions to be drawn, further studies will be needed that take into account the initial n-3 PUFA status of the subjects. Excessive n-3 PUFA intakes might be associated with a greater risk of peroxidation events and therefore neuropsychiatric deterioration. Indeed, some studies only recorded benefits when lower doses were administered. It is therefore important that the dose required to achieve any potential benefit be determined.

Key words: Omega 3: Behaviour: Neuropsychiatric disorders: Systematic review

There is biochemical evidence that n-3 polyunsaturated fatty acids (n-3 PUFA) play an important role in neural structure and function. The brain and central nervous system contain high concentrations of n-3 PUFA and several studies suggest a role for them in nervous system activity, the neuroplasticity of nerve membranes, synaptogenesis, synaptic transmission and neurotransmitter uptake(1). In fact, reduced blood levels of n-3 PUFA have been associated with a number of neuropsychiatric conditions, including attention deficit hyperactivity disorder (ADHD), Alzheimer’s disease, schizophrenia and depression(2,3). n-3 PUFA are available from dietary sources only; an insufficient intake may therefore be associated with psychiatric effects(4). Some evidence exists that suggests supplementation with individual n-3 PUFA or their combinations can reduced the intensity of the symptoms associated with certain neuropsychiatric conditions(5).

Nevertheless, although many studies find positive effects associated with supplementation, others do not find this benefit(6–8). It is worth mentioning that messages which recommend the use of n-3 PUFA supplements to prevent and reduce the risk of various diseases such as depression have spread rapidly among the population based on studies that find positive results(9). However, some aspects must be taken into account before releasing a general recommendation: if the effects are valid for both healthy and sick subjects and what doses and time of treatment are required to achieve the effects.

The aim of the present systematic review was to examine all published RCT investigating the effects of dietary supplementation with n-3 PUFA on the prevention and treatment of non-neurodegenerative neuropsychiatric conditions.

Experimental method
A computerized search was conducted for clinical trials in the Medlars Online International Literature (MEDLINE, via PubMed), the EMBASE®, the Latin American and Caribbean Heath Sciences Literature (LILACS), the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and the Cochrane databases. The search terms and equations used for the PubMed search were: “Fatty Acids, Omega-3”[Mesh] AND (“Depression”[Mesh] OR “Mood disorders”[Mesh]) OR “Attention Deficit Disorder with Hyperactivity”[Mesh], limited to ‘clinical trials’ and ‘humans’ (Fig. 1). Similar equations were
used with the other databases. The references in these returned articles were checked manually for further studies.

Report inclusion and data extraction

The titles and abstracts of the articles detected (n 182 detected by the 1st April 2011) were inspected independently by two researchers (AMLS and ERR) to select those relevant to the present work. Initial discrepancies between these researchers’ decisions were either resolved or a third reviewer (RMO) was called to make a judgement. Duplicates, review articles and non-relevant articles were excluded (n 122). Twenty two of the remaining 60 articles were rejected for the reasons shown in Fig. 1, which summarizes the inclusion/exclusion criteria of the work. The data of the 38 remaining articles were tabulated by all three of the above researchers. When data were incomplete, the corresponding authors were contacted and asked to provide the missing information. Tables 1–3 summarise the design of and the results provided by the 38 articles finally selected.

Because pregnancy is a specific physiological situation, data from studies about perinatal depression are presented separately from studies examining the effect of n-3 PUFA supplementation in depression at other stages of life (Table 2).

Results

Twenty three RCT (published since May 1999) examined the effect of n-3 PUFA supplementation on the prevention and treatment of non-perinatal depression (Table 1). The studies were heterogeneous in terms of sample size (which ranged from 14(10) to 302 subjects (11)). Two studies involved only women(12,13), and two only children (14,15). The diagnosis of the study subjects also varied, from major depressive disorder (MDD)(13,15–23), to bipolar disorder (BD)(10,14,24–26), depression but not MDD(12,27), depression with other pathologies(28–31) and healthy volunteers (31,32). The type and quantity of n-3 PUFA administered varied too, from 0·4 g/d(11) to 9·6 g/d(25). Six studies involved the administration of EPA (20 : 5n-3) only, employing doses of 1 g/d(16,19,21,24–28) to 6·6 g/d(14). Two studies involved the administration of DHA (22 : 6n-3) only(17,18). The remaining studies involved the administration of both EPA and DHA in varying quantities, with the EPA/DHA ratio ranging from 0·25(22) to 7(12,32). In some studies the subjects received no pharmacological treatment as part of the study(11–14,16,18,19,27,32), while in others (10,20) some drug was administered. In the majority of studies(15,20–26,28,30,31), however, the subjects continued with their normal treatment.

Six RCT (published since May 2003) examined the effect of n-3 PUFA supplementation on the prevention and treatment of perinatal depression (Table 2). Again, these were heterogeneous in terms of sample size, which ranged from 26(33) to 2999 subjects (34). Three studies were performed on pregnant women with MDD(4,33,35), analysing the effect of n-3 PUFA supplementation on the course of disease. The remaining trials all examined healthy women to determine the preventive effects of supplementation when given post-partum(36), pre-partum(34) and over both periods(37). The type and quantity of n-3 PUFA administered also differed widely. In one study only DHA(36) was given, in three studies different quantities of DHA + EPA(34,35,38) were given, in one DHA + EPA and an n-6 PUFA were given, and in one DHA + AA (20 : 4n-6) or DHA alone was given. The doses of n-3 PUFA given ranged from 0·2 g/d(36) to 3·4 g/d(35).

Nine RCT (published since August 2001) examined the effect of n-3 PUFA supplementation on the prevention and treatment of ADHD (Table 3). Again, the sample size was heterogeneous, with a range of 37(39) to 129(40) subjects. Five studies involved supplementation with n-3 and n-6 PUFA. Generally, supplementation with EPA and/or DHA was provided, except in one study(41) that involved supplementation with LA (18 : 2n-6) and ALA (18 : 3n-3). The dose of n-3 PUFA administered ranged from 0·345 g/d(32) to 1·4 g/d(39).
Table 1. Randomised controlled clinical trials of supplementation with n-3 PUFA in subjects with depression and related disorders

<table>
<thead>
<tr>
<th>Reference</th>
<th>Diagnosis</th>
<th>n (age, years)</th>
<th>Daily dose of n-3</th>
<th>Placebo</th>
<th>Drug Treatment</th>
<th>Length of trial (weeks)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antypa et al., 2009(32)</td>
<td>Healthy</td>
<td>56 (22-4 ± 3:8)</td>
<td>1740 mg EPA + 250 mg DHA</td>
<td>olive oil</td>
<td>None</td>
<td>4</td>
<td>Few effects on cognitive reactivity, risky decision-making or control/perfectionism score.</td>
</tr>
<tr>
<td>Bot et al., 2010(28)</td>
<td>MDD in diabetic patients</td>
<td>25 (18-75)</td>
<td>1000 mg EPA</td>
<td>rapeseed oil + medium chain triglycerides</td>
<td>Adjunct</td>
<td>12</td>
<td>No effect</td>
</tr>
<tr>
<td>Carney et al., 2009(29)</td>
<td>MDD in coronary heart disease BD (acute manic phase)</td>
<td>122 (58.3 ± 8.9)</td>
<td>930 mg EPA + 750 mg DHA</td>
<td>corn oil</td>
<td>50 mg sertraline</td>
<td>10</td>
<td>No effect</td>
</tr>
<tr>
<td>Chiu et al., 2005(10)</td>
<td>MDD in coronary heart disease</td>
<td>14 (NR)</td>
<td>930 mg EPA + 2200 mg DHA</td>
<td>olive oil</td>
<td>20 mg/kg/d valproate</td>
<td>4</td>
<td>No effect</td>
</tr>
<tr>
<td>da Silva et al., 2008(30)</td>
<td>MDD in Parkinson's disease</td>
<td>29 (49-78)</td>
<td>720 mg DHA</td>
<td>mineral oil</td>
<td>Adjunct in Parkinson's disease, none in healthy</td>
<td>12</td>
<td>Improvement in depression symptoms</td>
</tr>
<tr>
<td>Frangou et al., 2006(24)</td>
<td>BD I and II</td>
<td>75 (18-70)</td>
<td>1000 mg EPA / 2000 mg EPA</td>
<td>paraffin oil</td>
<td>None</td>
<td>12</td>
<td>Significant improvement with EPA. No difference between 1 g and 2 g of EPA</td>
</tr>
<tr>
<td>Freund-Levi et al., 2009(31)</td>
<td>Depression in Alzheimer disease BD I and II</td>
<td>204 (74 ± 9)</td>
<td>600 mg EPA + 1700 DHA</td>
<td>corn oil</td>
<td>ongoing usual treatment</td>
<td>26</td>
<td>No effect</td>
</tr>
<tr>
<td>Gracious et al., 2010(20)</td>
<td>Depression in Alzheimer disease BD I and II</td>
<td>51 (6-17)</td>
<td>6600 mg ALA</td>
<td>olive oil</td>
<td>None</td>
<td>16</td>
<td>No effect on sample as a whole, but a significant effect in the subgroup in which EPA blood levels improved</td>
</tr>
<tr>
<td>Jazayeri et al., 2008(16)</td>
<td>MDD</td>
<td>60 (20-59)</td>
<td>1000 mg EPA / 1000 mg EPA + 20 mg fluoxetine</td>
<td>rapeseed oil</td>
<td>None</td>
<td>8</td>
<td>Significant effect of EPA, similar to fluoxetine. EPA + fluoxetine combination was superior to either of the above alone.</td>
</tr>
<tr>
<td>Keck et al., 2006(25)</td>
<td>BD</td>
<td>116 (20-73)</td>
<td>6000 mg EPA</td>
<td>paraffin oil</td>
<td>Adjunct</td>
<td>16</td>
<td>No effect</td>
</tr>
<tr>
<td>Lucas et al., 2009(12)</td>
<td>PD and depression in menopause</td>
<td>120 women (40-55)</td>
<td>1050 mg EPA + 150 mg DHA</td>
<td>sunflower oil</td>
<td>None</td>
<td>8</td>
<td>Improvement in women with PD but without MDD at baseline</td>
</tr>
<tr>
<td>Marangell et al., 2003(17)</td>
<td>MDD</td>
<td>36 (18-65)</td>
<td>2000 mg DHA</td>
<td>NR</td>
<td>None</td>
<td>6</td>
<td>No effect</td>
</tr>
<tr>
<td>Mischoulon et al., 2008(18)</td>
<td>MDD</td>
<td>35 (18-80)</td>
<td>1000 mg DHA / 2000 mg DHA / 4000 mg DHA</td>
<td>corn and soy oil</td>
<td>None</td>
<td>12</td>
<td>Positive effect at lower doses</td>
</tr>
<tr>
<td>Mischoulon et al., 2009(19)</td>
<td>MDD</td>
<td>57 (18-80)</td>
<td>1000 mg EPA</td>
<td>paraffin oil</td>
<td>None</td>
<td>8</td>
<td>No effect</td>
</tr>
<tr>
<td>Nemets et al., 2002(20)</td>
<td>MDD</td>
<td>20 (18-75)</td>
<td>2000 mg EPA</td>
<td>not specified</td>
<td>Adjunct</td>
<td>4</td>
<td>Significant effects after 3 week of treatment</td>
</tr>
<tr>
<td>Nemets et al., 2006(13)</td>
<td>MDD</td>
<td>28 (6-12)</td>
<td>380-400 mg EPA + 180-200 mg DHA</td>
<td>olive oil or safflower oil</td>
<td>Adjunct in 5 children, none in the rest</td>
<td>16</td>
<td>Highly significant effects of omega-3</td>
</tr>
<tr>
<td>Peet and Horrobin, 2002(21)</td>
<td>MDD</td>
<td>70 (18-70)</td>
<td>1000 mg EPA / 2000 mg EPA / 4000 mg EPA</td>
<td>paraffin oil</td>
<td>Adjunct</td>
<td>12</td>
<td>Clear effect with 1000 mg EPA</td>
</tr>
<tr>
<td>Rogers et al., 2006(27)</td>
<td>Mild to moderate depression</td>
<td>218 (18-70)</td>
<td>630 mg EPA + 850 mg DHA</td>
<td>olive oil</td>
<td>None</td>
<td>12</td>
<td>No effect</td>
</tr>
</tbody>
</table>
In five studies (39–41,43,44) the subjects received no pharmacological treatment, in one a stimulant medication (42) was provided, and in two (45,46) the subjects continued with their normal medication.

Discussion

n-3 PUFA and depression disorders

Depression is very common – one in five people become depressed at some point in their lives (47). A significant proportion (10–20%) of patients do not respond at all or respond poorly to therapy (48); useful prevention and treatment strategies are therefore a priority.

Although observational studies have indicated that depression is associated with lower levels of total n-3 PUFA and those of both EPA and DHA (49), only two studies were found that analysed the role of n-3 PUFA supplements in healthy persons, the results of which were not conclusive.

Van de Rest et al. (11) reported no effect on mental well-being for either of two doses of n-3 PUFA administered (0.4 g/d and 2.0 g/d) compared to a placebo. In contrast, Antipa et al. (32) reported a positive effect of supplementation on cognitive reactivity, risky decision-making and control/perfectionism score. The dose of n-3 PUFA used in the latter work was also 2 g/d, although the EPA/DHA ratio was higher (7.0 compared to 1.3).

The majority of studies, which employed doses of up to 2.5 g/d, performed on patients with depression, MDD or BD who received no pharmacological treatment, recorded a positive effect for EPA supplementation (10,12), DHA supplementation (18), and their combination (12,13). Gracious et al. (14) also reported a positive effect, but for a dose of 6.6 g/d EPA. Those studies that found no difference in effect between the administration of n-3 PUFA and placebo also employed low/moderate doses of n-3 PUFA (17,19,27) (up to 2 g/d). However, the EPA/DHA ratio was much higher in those that found positive effects (EPA/DHA = 2.0–7.0) compared to those that found no effect (EPA/DHA = 0.7) (27).

More trials report a positive effect for n-3 PUFA supplementation as an adjunct therapy (15,20,21,24,26) than those that found no effect (22,25). As in those studies that involved n-3 PUFA supplementation only, those that found this positive effect involved lower doses of EPA (<2.0 g/d) or a higher EPA/DHA ratio (2.0 vs. 0.25 in positive and negative trials respectively). Carney et al. (29) (who administered sertraline) and Chiu et al. (10) (who used valproate) found no evidence that n-3 PUFA increased the effect of medication on depression or manic phase BD symptoms.

The trials that involved n-3 PUFA administration with and without pharmacological treatment found EPA to produce more promising results with respect to the improvement of depression symptoms than DHA monotherapy (50,51). A specific ratio of EPA/DHA might be the most effective (28). However, whereas increased n-3 PUFA intake might alleviate depressive symptoms, there is little evidence it is of any benefit in the treatment of mania (10,52).

Table 1. Continued

<table>
<thead>
<tr>
<th>Reference</th>
<th>Diagnosis</th>
<th>n (age, years)</th>
<th>Daily dose of n-3</th>
<th>Length of trial (weeks)</th>
<th>Outcome</th>
<th>Drug Treatment</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rondanelli et al., 2010 (13)</td>
<td>MDD or dysthymia</td>
<td>46 (65-90)</td>
<td>1670 mg EPA + 630 mg DHA</td>
<td>16</td>
<td>Significant improvement with supplementation</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Silvers et al., 2005 (22)</td>
<td>MDD</td>
<td>77 (18-65)</td>
<td>600 mg EPA + 2400 mg DHA</td>
<td>12</td>
<td>No effect</td>
<td>Adjunct</td>
<td></td>
</tr>
<tr>
<td>Stoll et al., 1999 (26)</td>
<td>BD I and II</td>
<td>30 (18-65)</td>
<td>4400 mg EPA + 2200 mg DHA</td>
<td>16</td>
<td>Significant symptom reduction and better outcome</td>
<td>Adjunct</td>
<td></td>
</tr>
<tr>
<td>Su et al., 2003 (23)</td>
<td>MDD</td>
<td>28 (18-60)</td>
<td>1800 mg EPA + 900 mg DHA</td>
<td>8</td>
<td>Significant improvement with supplementation</td>
<td>Adjunct</td>
<td></td>
</tr>
<tr>
<td>van de Rest et al., 2008 (11)</td>
<td>Healthy</td>
<td>302 (65-90)</td>
<td>1800 mg EPA + 400 mg DHA</td>
<td>26</td>
<td>No effect</td>
<td>Adjunct</td>
<td></td>
</tr>
</tbody>
</table>

MDD = major depression disorder; BD = bipolar disorder; PD = psychological distress; NR = not reported

R. M. Ortega et al.
Depression is a common co-morbid disorder in both type 1 and type 2 diabetes mellitus\(^{(28)}\), but a considerable percentage of diabetic subjects receiving antidepressant drugs does not achieve full remission\(^{(55)}\). Depression is also frequent in patients with Parkinson Disease\(^{(54,55)}\), but antidepressant treatment given in addition to Parkinson's medication can often result in collateral effects and adverse reactions\(^{(56)}\). Depression may also occur in the early stages of Alzheimer disease\(^{(57)}\). However, very few studies have been performed in such patients. Bot et al.\(^{(38)}\) found no evidence of a therapeutic effect of 1.0 g/d ethyl-EPA as an add-on to antidepressant medication compared to placebo in diabetic patients with depression, and Freund-Levi et al.\(^{(51)}\) observed no positive effect on depression symptoms in patients with Alzheimer disease. However, in these trials, patients continued with their usual treatment for depression, and this may have masked small effects of treatment with n-3 PUFA. Certainly, da Silva et al.\(^{(30)}\) found that an EPA/DHA ratio of 1:5 improved depressive symptoms in patients with Parkinson disease, even in those who had already been taking antidepressant medication for over a year but still suffered major depression diagnosis.

**n-3 PUFA supplementation and perinatal depression**

Pregnancy leads to several changes in n-3 PUFA status, including a depletion of maternal plasma DHA under normal dietary conditions, that persist after delivery\(^{(58)}\). Mothers may be at higher risk of post-partum depression when they become depleted in n-3 PUFA, especially DHA, and certainly, depression is quite common in the post-partum period\(^{(59)}\). The studies described in Table 2 all investigate the possible effects of n-3 PUFA supplementation on the prevention and treatment of perinatal depression.

In studies involving healthy women, supplementation was found not to be associated with any effect on the prevention of depression during\(^{(37)}\) or after\(^{(34,36,37)}\) pregnancy. Llorente et al.\(^{(36)}\) used supplements of DHA at a dose of 200 mg/d with no other treatment, and observed no effect on the incidence of postpartum depression, while Doornbos et al.\(^{(57)}\) used supplements of DHA (220 mg/d) or DHA + AA (220 mg/d each), and found them to have no effect either (Table 2). This may have been because no EPA was provided in these studies, or simply because of their small sample sizes. Makrides et al.\(^{(34)}\) overcame some of the limitations of these studies, such as the low dose of DHA given, the absence of EPA in supplements, and small sample size. However, even when 800 mg/d DHA were provided, along with 100 mg/d EPA, no reduction in the prevention of postpartum depression was seen.

In pregnant women diagnosed with perinatal depression, supplementation was associated with no improvement in symptoms in some studies\(^{(55,55,38)}\) (Table 2). For example, Freeman et al.\(^{(38)}\) reported no improvements with a dose of EPA + DHA of 1.9 g/d, and Rees et al.\(^{(35)}\) observed none after providing 6 g/d of fish oil (414 mg EPA + 1638 mg DHA). The only study to report some improvement in symptoms was that of Su et al.\(^{(35)}\). The main difference between

---

**Table 2. Randomized controlled clinical trials of supplementation with n-3 PUFA in patients with perinatal depression**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Diagnosis</th>
<th>n (age, years)</th>
<th>Daily dose of PUFA</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doornbos et al.(^{(28)})</td>
<td>Healthy</td>
<td>59 (18-45)</td>
<td>220 mg DHA / 220 mg AA</td>
<td>No effect</td>
</tr>
<tr>
<td>Freeman et al.(^{(38)})</td>
<td>Healthy</td>
<td>119 (NR)</td>
<td>1100 mg EPA + 800 mg AA</td>
<td>No effect</td>
</tr>
<tr>
<td>Llorente et al.(^{(36)})</td>
<td>Healthy</td>
<td>2399 (28-56)</td>
<td>200 mg DHA</td>
<td>No effect</td>
</tr>
<tr>
<td>Makrides et al.(^{(34)})</td>
<td>MDD in pregnancy</td>
<td>26 (21-45)</td>
<td>414 mg EPA + 1638 mg DHA</td>
<td>No effect</td>
</tr>
<tr>
<td>Rees et al.(^{(35)})</td>
<td>Healthy</td>
<td>36 (18-40)</td>
<td>2300 mg EPA + 1200 mg DHA</td>
<td>No effect</td>
</tr>
<tr>
<td>Su et al.(^{(35)})</td>
<td>MDD in pregnancy</td>
<td>36 (18-40)</td>
<td>2300 mg EPA + 1200 mg DHA</td>
<td>No effect</td>
</tr>
</tbody>
</table>

MDD = major depression disorder; NR = not reported.
Table 3. Randomised controlled clinical trials of supplementation with n-3 PUFA in children with ADHD

<table>
<thead>
<tr>
<th>Reference, Year(s)</th>
<th>Diagnosis</th>
<th>n (age, years)</th>
<th>Daily dose of PUFA</th>
<th>Placebo</th>
<th>Drug Treatment</th>
<th>Length of trial (weeks)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bélanger et al., 2009(39)</td>
<td>DSM-IV ADHD</td>
<td>37 (6-12)</td>
<td>500-1000 mg EPA + 200-400 mg DHA (according to body weight)</td>
<td>sunflower oil</td>
<td>none</td>
<td>8 + 8</td>
<td>No effect of treatment</td>
</tr>
<tr>
<td>Gustafsson et al., 2010(43)</td>
<td>DSM-IV ADHD</td>
<td>92 (7-12)</td>
<td>500 mg EPA + 2.7 mg DHA</td>
<td>rapeseed oil + medium-chain triglycerides</td>
<td>none</td>
<td>15</td>
<td>No significant effect on sample as a whole, but improvement in subgroup of children with oppositional behaviour and less impulsiveness/hyperactivity</td>
</tr>
<tr>
<td>Hirayama et al., 2004(45)</td>
<td>DSM-IV ADHD + ADHD-suspected</td>
<td>40 (6-12)</td>
<td>500 mg DHA + 100 mg EPA (added to foods)</td>
<td>Non-enriched foods</td>
<td>Ongoing usual treatment</td>
<td>8.5</td>
<td>No effect of treatment</td>
</tr>
<tr>
<td>Johnson et al., 2009 (phase 1)(44)</td>
<td>DSM-IV ADHD</td>
<td>82 (8-18)</td>
<td>558 mg EPA + 174 mg DHA + 60 mg GLA</td>
<td>olive oil</td>
<td>none</td>
<td>12</td>
<td>No significant effect on sample as a whole, but improvement in subgroup of children with ADHD inattentive subtype and comorbid neurodevelopmental disorders</td>
</tr>
<tr>
<td>Raz y col., 2009(41)</td>
<td>AFA and DSM-IV ADHD-like symptoms + learning disabilities</td>
<td>73 (7-13)</td>
<td>480 mg of LA + 120 mg of ALA</td>
<td>1000 mg Vit C</td>
<td>none</td>
<td>7</td>
<td>No effect of treatment</td>
</tr>
<tr>
<td>Richardson and Puri., 2002(46)</td>
<td>ADHD-like symptoms + learning disabilities</td>
<td>41 (6-12)</td>
<td>186 mg EPA + 480 mg DHA + 96 mg GLA + 864 mg LA + 42 mg AA</td>
<td>olive oil</td>
<td>none</td>
<td>12</td>
<td>Significant effect on symptoms</td>
</tr>
<tr>
<td>Sinn and Bryan, 2007 (phase 1)(40)</td>
<td>Score ≥ 2 SD above average Conners ADHD Index</td>
<td>129 (7-12)</td>
<td>LC-PUFA (558 mg EPA + 174 mg DHA + 60 mg GLA)</td>
<td>Palm oil</td>
<td>none</td>
<td>15</td>
<td>Improvement in parent ratings of ADHD-related symptoms; no improvements in teacher reports</td>
</tr>
<tr>
<td>Stevens et al., 2003(42)</td>
<td>ADHD-like symptoms + EFA deficiency</td>
<td>47 (6-13)</td>
<td>480 mg DHA + 80 mg EPA + 40 mg AA + 96 mg GLA</td>
<td>olive oil</td>
<td>ongoing usual treatment</td>
<td>17.5</td>
<td>Significant improvements only in 2 of 16 outcome measures</td>
</tr>
<tr>
<td>Voigt et al., 2001(42)</td>
<td>DSM-IV ADHD</td>
<td>63 (6-12)</td>
<td>345 mg DHA</td>
<td>Not specified</td>
<td>Adjunctive</td>
<td>17.5</td>
<td>No effect</td>
</tr>
</tbody>
</table>

GLA: gamma linolenic acid
this and the previous two studies was that the dose of n-3 PUFA administered and the EPA/DHA ratio (1:8) were higher, and that the Hawthorn effect (a high response in the control group)\(^{(60)}\) was avoided by not including those individuals in the randomisation procedure who, after a single-blind placebo run-in of 1 week, showed a strong placebo response.

Although the use of n-3 PUFA supplements in depressed pregnant women at the above doses does not appear to improve symptoms, there is insufficient evidence to confirm this at present. New trials should be undertaken in which the consumption of fish is controlled since this has the potential to confound the results. In such trials, depressed pregnant women should be provided with an n-3 PUFA supplement with an adequate EPA/DHA ratio, and an adequate control group should be present. The involvement of depressed pregnant women with an inadequate n-3 PUFA status might also be useful. Certainly, future studies should examine the improvement in gestational diabetes since, in the general population, diabetes is associated with a greater risk of depression\(^{(28)}\).

### n-3 PUFA supplementation and ADHD

The link between ADHD and n-3 PUFA deficiency was first proposed by Colquhoun & Bunday\(^{(61)}\). Since then, a number of researchers have reported lower n-3 PUFA levels in children with ADHD than in healthy controls\(^{(62–66)}\), and different supplementation can improve symptoms. Even the best have been doses employed. Although the fatty acid composition of the plasma and erythrocytes could change over such short periods, the turnover of fatty acids in the brain is likely to be quite low in children. Longer periods of supplementation and/or larger supplements might be required for any change in the fatty acid content of the central nervous system to be seen.

Given the above, and in agreement with that stated in a recent review by Raz & Gabis\(^{(67)}\), support for the use of essential fatty acids (EFA) supplements in children with ADHD will require further studies with more rigorous methodologies, proper ADHD diagnosis, known baseline fatty acid status, behavioural assessment in more than one setting, to be blinded (unfortunately problematic with fish oil supplements), and to involve adequate sample sizes and supplementation periods.

### Omega 3 and other neuropsychiatric and behavioral disorders

Although initially 3 papers were excluded because they did not fit the inclusion criteria, we find interesting the topics addressed and deserve to be mentioned. The first study is a research conducted in 30 women with borderline personality disorder\(^{(68)}\). The main finding is that those women who received 1 g of ethyl-EPA (E-EPA) daily for 8 weeks experienced a greater decrease in depressive and aggressive symptoms than those receiving placebo (mineral oil). In other study, the effect of n-3 PUFA was analyzed in eleven patients with current obsessive-compulsive disorder, who were randomly allocated to 6 weeks of placebo (2 g/day of liquid paraffin) followed by 6 weeks of 2 g/day of EPA, or to EPA followed by placebo\(^{(69)}\). The authors didn’t find significant effect of the supplement. According with the author’s conclusion, one of the reasons for its ineffectiveness could be a low EPA dose. The last work studied the effect of n-3 on the Developmental Coordination Disorder\(^{(70)}\). In this study, 117 children aged 5 to 12 years were given a supplement with an omega 3:6 ratio of 4:1 or a placebo for 3 months, followed by a period for 3 months in which all participants received the supplement. Although there were not improvements on motor skills, improvements for active treatment versus placebo were found in reading, spelling, and behaviour over the 3 months of treatment. After the crossover, similar changes were seen in the placebo-active group, whereas children continuing with active treatment maintained or improved their progress. In view of these results is interesting to note the possible use of n-3 in the treatment of some neuropsychiatric and behavioural disorders, yet little studied.

### Conclusions

In conclusion, the results of the articles examined in the present work regarding the effect of n-3 PUFA supplementation on the prevention and treatment of non-neurodegenerative neuropsychiatric disorders are inconclusive, although it would seem plausible that such supplementation could provide some benefit.
Having in mind the data of the present review, most of the existing studies do not meet important requirements to elucidate the effect of n-3 PUFA on the prevention and treatment of non-neurodegenerative neuropsychiatric disorders. Future studies should include: a sample size justified by an adequate sample size predetermination (specific to the group under study); the assessment of basal situation in n-3 PUFA in order to include only those patients with a status that could be improved; an appropriate selection criteria (healthy or sick subjects, with or without drug treatment...); control of dietary intake during the intervention, since changes in other nutrients may modify the results of the intervention; and the study of changes in erythrocytes n-3 PUFA levels in order to determine whether dietary intervention corresponds with changes in biochemical parameters. In addition, according with the studies included in the present review, the ratio EPA/DHA should be higher than 1.5-2 and future studies should be long enough to ensure that biochemical changes lead to a functional change (in both behavior or neuropsychiatric disorders). Thus, improving the design of future studies is essential to reach conclusive results.

Acknowledgements

R. M. O. and A. M. L. S. contributed to the planning of the search of this review, A. M. L. S. and E. R. R. decided the analysis and presentation of the results and created the quality assessment tool of the articles. All authors were involved in the analyses of the articles. A. M. L. S. and E. R. R. wrote the introduction and methodology of the first manuscript. All authors wrote the results section and revised and discussed all drafts and approved the final manuscript. There are no conflicts of interest to report. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

References

eicosapentaenoic acid in bipolar depression: randomised

randomized, placebo-controlled trials of ethyl-eicosapenta-
tanoate in the treatment of bipolar depression and rapid
cycling bipolar disorder. *Biol Psychiatry* 60, 1020–1022.

fatty acids in bipolar disorder: a preliminary double-blind,
placebo-controlled trial. *Arch Gen Psychiatry* 56, 407–412.

n-3 long-chain polyunsaturated fatty acid (EPA and DHA)
supplementation on depressed mood and cognitive func-

acid as an add-on to antidepressant medication for co-
morbid major depression in patients with diabetes mellitus: a
randomized, double-blind placebo-controlled study. *J Affect
Disord* 126, 282–286.

augmentation of sertraline in treatment of depression in
patients with coronary heart disease: a randomized controlled
trial. *JAMA* 302, 1651–1657.

in Parkinson’s disease: a double-blind, randomized,
placebo-controlled pilot study of omega-3 fatty-acid supple-

supplementation in mild to moderate Alzheimer’s disease:
effects on neuropsychiatric symptoms. *Int J Geriatr Psychiatry*
23, 161–169.

fatty acids (fish-oil) and depression-related cognition in

33. Rees AM, Austin MP & Parker GB (2008) Omega-3 fatty
acids as a treatment for perinatal depression: randomised
double-blind placebo-controlled trial. *Aust N Z J Psychiatry*
42, 199–205.

DHA supplementation during pregnancy on maternal
depression and neurodevelopment of young children: a
randomized controlled trial. *JAMA* 304, 1675–1683.

for major depressive disorder during pregnancy: results from
a randomized, double-blind, placebo-controlled trial. *J Clin
Psychiatry* 69, 644–651.

maternal docosahexaenoic acid supplementation on post-

Supplementation of a low dose of DHA or DHA + AA
does not prevent peripartum depressive symptoms in
a small population based sample. *Prog Neuropsychopharmacol
Biol Psychiatry* 33, 49–52.

acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. *J Affect
Disord* 110, 142–148.

acid treatment of children with attention-deficit hyperactivity
disorder: A randomized, double-blind, placebo-controlled

40. Sinn N & Bryan J (2007) Effect of supplementation with poly-
unsaturated fatty acids and micronutrients on learning and

chain essential fatty acids on children with attention-deficit/
hyperlactivity disorder: a double-blind placebo-controlled

42. Voigt RG, Llorente AM, Jensen CL, *et al.* (2001) A random-
dized, double-blind, placebo-controlled trial of docosahexae-
noic acid supplementation in children with attention-deficit/

EPA supplementation improves teacher-rated behaviour

omega-6 fatty acids for attention deficit hyperactivity disorder:
a randomized placebo-controlled study in children and adoles-

osahexaenoic acid-containing food administration on symp-
toms of attention-deficit/hyperactivity disorder - a placebo-

placebo-controlled study of the effects of supplementation
with highly unsaturated fatty acids on ADHD-related symp-
toms in children with specific learning difficulties. *Prog Neu-
ropsychopharmacol Biol Psychiatry* 26, 233–239.

anxiety, depression, and substance use disorders in an
urban general medicine practice. *Arch Fam Med* 9, 876–883.


49. Lin PY & Su KP (2007) A meta-analytic review of double-
blind, placebo-controlled trials of antidepressant efficacy of

bad mood. Could we treat and prevent depression in Type 2
diabetes by means of omega-3 polyunsaturated fatty acids?

51. Martins JG (2009) EPA but not DHA appears to be respon-
sible for the efficacy of omega-3 long chain polyunsaturated
fatty acid supplementation in depression: evidence from a

52. Hegarty BD & Parker GB (2011) Marine omega-3 fatty acids
and mood disorders - linking the sea and the soul: ‘Food for

53. Lustman PJ & Clouse RE (2002) Treatment of depression in
patients with coronary heart disease: a randomized controlled

associated with depression in Parkinson’s disease: a cross-
 sectional study in a Polish population. *Eur Psychiatry* 21, 516–520.

55. Vajda FJ & Solinas C (2005) Current approaches to manage-

56. McKeith I & Cummings J (2005) Behavioural changes and


